Lauren P Jatt,Kevin M Gillespie,Phuong Van,Stephen L Hoffman,Lisa A Jackson,Sean C Murphy,James R Heath,James G Kublin
{"title":"论文标题:在控制人类疟疾感染的孢子虫疟疾疫苗试验中,细胞因子与中度和重度不良事件相关。","authors":"Lauren P Jatt,Kevin M Gillespie,Phuong Van,Stephen L Hoffman,Lisa A Jackson,Sean C Murphy,James R Heath,James G Kublin","doi":"10.1093/infdis/jiaf435","DOIUrl":null,"url":null,"abstract":"Ensuring the safety and efficacy of candidate vaccines is critical. Although mechanisms underpinning protective immune responses to malaria vaccines are frequently investigated, immune responses correlating with moderate and severe adverse events are rarely examined. Here, we leverage a malaria vaccine trial with a higher-than-expected adverse event rate and frequent sampling to investigate cytokine profiles associated with adverse events. We found that Interleukin-6 was elevated on days in which individuals experienced moderate and severe adverse events. More research on immune responses associated with adverse events is warranted in order to identify biomarkers associated with systemic reactogenicity and accelerate vaccine development.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"70 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Manuscript title: Cytokines Associated With Moderate and Severe Adverse Events During a Sporozoite Malaria Vaccine Trial with Controlled Human Malaria Infection.\",\"authors\":\"Lauren P Jatt,Kevin M Gillespie,Phuong Van,Stephen L Hoffman,Lisa A Jackson,Sean C Murphy,James R Heath,James G Kublin\",\"doi\":\"10.1093/infdis/jiaf435\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ensuring the safety and efficacy of candidate vaccines is critical. Although mechanisms underpinning protective immune responses to malaria vaccines are frequently investigated, immune responses correlating with moderate and severe adverse events are rarely examined. Here, we leverage a malaria vaccine trial with a higher-than-expected adverse event rate and frequent sampling to investigate cytokine profiles associated with adverse events. We found that Interleukin-6 was elevated on days in which individuals experienced moderate and severe adverse events. More research on immune responses associated with adverse events is warranted in order to identify biomarkers associated with systemic reactogenicity and accelerate vaccine development.\",\"PeriodicalId\":501010,\"journal\":{\"name\":\"The Journal of Infectious Diseases\",\"volume\":\"70 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Infectious Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/infdis/jiaf435\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/infdis/jiaf435","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Manuscript title: Cytokines Associated With Moderate and Severe Adverse Events During a Sporozoite Malaria Vaccine Trial with Controlled Human Malaria Infection.
Ensuring the safety and efficacy of candidate vaccines is critical. Although mechanisms underpinning protective immune responses to malaria vaccines are frequently investigated, immune responses correlating with moderate and severe adverse events are rarely examined. Here, we leverage a malaria vaccine trial with a higher-than-expected adverse event rate and frequent sampling to investigate cytokine profiles associated with adverse events. We found that Interleukin-6 was elevated on days in which individuals experienced moderate and severe adverse events. More research on immune responses associated with adverse events is warranted in order to identify biomarkers associated with systemic reactogenicity and accelerate vaccine development.